Pendulum

Pendulum Therapeutics is the leading innovator in microbiome science, delivering research-based probiotic formulations to support metabolic health. The company leverages cutting-edge research and strong intellectual property to bring effective, science-backed solutions to consumers worldwide. Pendulum Akkermansia was the first novel probiotic species brought to market in more than 50 years and is the first and only probiotic clinically proven to lower A1C and blood glucose in people with type 2 diabetes by stimulating natural GLP-1 production. The product line includes Metabolic Daily, Akkermansia, Glucose Control, and Polyphenol Booster, sold direct-to-consumer and through healthcare provider channels.